Cargando…

Medication Adherence and Asthma Control with Once-Daily Indacaterol/Glycopyrronium/Mometasone Furoate Breezhaler Digital Companion: 90-Day Analysis from Germany

INTRODUCTION: Suboptimal adherence to inhaled asthma therapy is associated with poor clinical outcomes. Digital companion paired inhaler devices record medication use and provide reminders, thereby improving treatment adherence and asthma outcomes. This analysis assessed the impact of indacaterol/gl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woehrle, Holger, Mastoridis, Paul, Stempel, David, Kaye, Leanne, Vuong, Vy, Mezzi, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10447847/ https://www.ncbi.nlm.nih.gov/pubmed/37120785 http://dx.doi.org/10.1007/s41030-023-00225-z

Ejemplares similares

Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler(®) Device in Patients with Asthma
por: Bartels, Christian, et al.
Publicado: (2021)

Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma
por: Chapman, Kenneth R., et al.
Publicado: (2021)

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
por: Mtibaa, Mondher, et al.
Publicado: (2021)

Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects
por: Inoue, Satoru, et al.
Publicado: (2021)

Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial
por: Beier, Jutta, et al.
Publicado: (2021)

Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses
por: van Zyl-Smit, Richard N., et al.
Publicado: (2023)

Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study
por: Watz, Henrik, et al.
Publicado: (2020)

A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma
por: Brittain, Dominic, et al.
Publicado: (2022)

Effect of once-daily indacaterol maleate/mometasone furoate on exacerbation risk in adolescent and adult asthma: a double-blind randomised controlled trial
por: Beasley, Richard W, et al.
Publicado: (2015)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Efficacy of mometasone furoate and fluticasone furoate on persistent allergic rhinoconjunctivitis
por: Aneeza, W. Hamizan, et al.
Publicado: (2013)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Mometasone furoate in the management of asthma: a review
por: Tan, Ricardo A, et al.
Publicado: (2008)

Effectiveness of 0.1% mometasone furoate under hydrocolloid dressing versus 0.1% mometasone furoate in patients with lichen simplex chronicus
por: Lo, Hiu Lai, et al.
Publicado: (2023)

Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
por: Halpin, David M.G., et al.
Publicado: (2021)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Mometasone furoate nasal spray: a systematic review
por: Passali, Desiderio, et al.
Publicado: (2016)

Mometasone furoate is not superior to saline for chronic rhinitis in the elderly
por: Carvalho, Victor, et al.
Publicado: (2019)

Nasal Absorption Enhancement of Mometasone Furoate Nanocrystal Dispersions
por: Masuda, Shuya, et al.
Publicado: (2023)

Zein nanoparticles as oral carrier for mometasone furoate delivery
por: Zimath, Priscila, et al.
Publicado: (2023)

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study
por: Anzueto, Antonio R., et al.
Publicado: (2018)

Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease
por: Kosoglou, Teddy, et al.
Publicado: (2013)

Development of simple and fast UV-method for the quantitative determination of mometasone furoate in a large number of metered doses of an aqueous nasal spray of mometasone furoate
por: Levin, Mykhaylo, et al.
Publicado: (2019)

Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population
por: Sagara, Hironori, et al.
Publicado: (2021)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016)

Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation
por: Lage, Nayara Almeida, et al.
Publicado: (2023)

Suppression of Cytokine Release by Fluticasone Furoate vs. Mometasone Furoate in Human Nasal Tissue Ex-Vivo
por: Zhang, Nan, et al.
Publicado: (2014)

A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis
por: Yanez, Anahi, et al.
Publicado: (2016)

Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis
por: Doulaptsi, Maria, et al.
Publicado: (2021)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

Significant receptor affinities of metabolites and a degradation product of mometasone furoate
por: Valotis, Anagnostis, et al.
Publicado: (2004)

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease
por: Calverley, Peter MA, et al.
Publicado: (2008)

Development and evaluation of solid lipid nanoparticles of mometasone furoate for topical delivery
por: Madan, Jyotsana R, et al.
Publicado: (2014)

Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids
por: Spada, Fabrizio, et al.
Publicado: (2018)

Effects of intranasal mometasone furoate on blood pressure in patients with allergic rhinitis
por: Kartal, O., et al.
Publicado: (2018)

New Vehiculation Systems of Mometasone Furoate for the Treatment of Inflammatory Skin Diseases
por: Taléns-Visconti, Raquel, et al.
Publicado: (2022)

Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study
por: Wedzicha, Jadwiga A., et al.
Publicado: (2019)

Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma
por: van Zyl-Smit, Richard N, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rpq42kcca3kpigp55a5vvj8uic